|
|
|
|
|
CEOCFO CEOCFO Monthly Analyst |
PacificHealth Labs, Inc. - developing
and marketing innovative science based nutritional products for sports performance, Healthcare PacificHealth Labs, Inc.
Interview conducted
by CEOCFOinterviews,com BIO OF
CEO
Dr. Robert Portman received a Ph.D. in biochemistry from Virginia Tech. He then worked as a senior scientist for Schering-Plough Corporation and Hoechst-Roussel Pharmaceuticals Inc. In 1974 Dr. Robert Portman founded MED Communications, an advertising agency which specialized in healthcare for pharmaceutical and diagnostic companies. In 1988 Dr. Robert Portman founded a consumer-advertising agency. In 1995 Dr. Robert Portman founded PacificHealth Laboratories, Inc. (PHLI) a nutrition technology company focused on the research and development of proprietary products for sports performance, weight loss and the treatment of Type 2 diabetes. About PacificHealth Labs,
Inc. PacificHealth
Laboratories, Inc. (PHLI) is a science based nutrition company that focuses on the
development of proprietary products for sports performance
weight loss/management and control of Type 2 diabetes. But
unlike conventional sports drinks, ACCELERADE
contains the patented 4 to 1 ratio of carbohydrate to protein to speed the movement of
carbohydrate into the muscle and the ideal combination of simple and complex carbohydrates
for rapid and sustained energy. By increasing the energy efficiency of every gram of
carbohydrate consumed, ACCELERADE conserves
muscle glycogen and improves endurance. Studies show that, compared to a conventional
sports drink, ACCELERADE extends endurance by 24%..
ACCELERADE was based on the same science that
resulting in Endurox R4 the Company’s first
sports drink. Endurox R4 has been shown to speed recovery following exercise
and improve performance up to 55% in a subsequent exercise bout. In November 1998 the Company was granted a patent
(U.S. 6,051,235). Dr. Portman: PacificHealth Labs was founded in 1995.Our
mission was to develop and market innovative nutritional products that were science based
in three areas, sports nutrition, weight loss and Type 2 diabetes. Dr. Portman: We began a weight loss research program a number of years ago. The goal- to develop a proprietary formulation that would stimulate the body’s natural satiety peptide, which is called cholecystokinin (CCK). Researchers have known for 30 years that CCK is the primary controller of appetite in humans. If we would turn on this particular peptide. We could help overweight individuals eat less and lose weight safely. This research came to fruition last year when we introduced our first product, called Satietrol®. Satietrol® is the first product specifically designed to stimulate CCK. Satietrol is taken 10 to 15 minutes before a meal. We’ve done some extensive clinical trials, and are able to show that Satietrol, taken before a meal reduces hunger up to 43% up to 4 hours after eating. and reduces calorie intake in a subsequent meal up to 48%. This is a completely new class of diet products. It is not a stimulant.The study of satiety peptides represents one of the hottest areas of research in weight loss We were out there with the first one. We have a novel technology to help individuals lose weight. CEOCFOinterviews – What makes Satietrol® different from Slim Fast? Dr. Portman: What
differentiates us is that we have a product that reduces appetite. Slim Fast is simply a
220 calorie meal substitute.. It’s convenient, but it has no real effect on
controlling appetite.
|
